ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Pyrrolopyridine Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2)

View Author Information
Pfizer Global Research and Development, St. Louis Laboratories, 700 Chesterfield Parkway W, Chesterfield, Missouri 63017
Cite this: J. Med. Chem. 2007, 50, 11, 2647–2654
Publication Date (Web):May 5, 2007
Copyright © 2007 American Chemical Society

    Article Views





    Other access options
    Supporting Info (1)»


    Abstract Image

    A new class of potent kinase inhibitors selective for mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2 or MK-2) for the treatment of rheumatoid arthritis has been prepared and evaluated. These inhibitors have IC50 values as low as 10 nM against the target and have good selectivity profiles against a number of kinases including CDK2, ERK, JNK, and p38. These MK-2 inhibitors have been shown to suppress TNFα production in U397 cells and to be efficacious in an acute inflammation model. The structure−activity relationships of this series, the selectivity for MK-2 and their activity in both in vitro and in vivo models are discussed. The observed selectivity is discussed with the aid of an MK-2/inhibitor crystal structure.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.


     To whom correspondence should be addressed. Phone:  636-247-7651 (D.R.A.); 636-247-7672 (M.J.M.). Fax:  636-247-5400 (D.R.A.); 636-247-6953 (M.J.M.). E-mail:  [email protected] (D.R.A.); [email protected] (M.J.M.).

    Supporting Information Available

    Jump To

    Combustion analysis data, kinase selectivity assay protocols, CACO-2 assay protocols, ATP competition experiments, and Km determinations. This material is available free of charge via the Internet at

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

    Cited By

    This article is cited by 145 publications.

    1. Liam S. Sharninghausen, Allen F. Brooks, Wade P. Winton, Katarina J. Makaravage, Peter J. H. Scott, Melanie S. Sanford. NHC-Copper Mediated Ligand-Directed Radiofluorination of Aryl Halides. Journal of the American Chemical Society 2020, 142 (16) , 7362-7367.
    2. Zhiguo Zhang, Xiaolong Gao, Yameng Wan, Yuanyuan Huang, Guoqing Huang, and Guisheng Zhang . Ammonium Acetate-Promoted One-Pot Tandem Aldol Condensation/Aza-Addition Reactions: Synthesis of 2,3,6,7-Tetrahydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones. ACS Omega 2017, 2 (10) , 6844-6851.
    3. Jimil George, Hun Young Kim, and Kyungsoo Oh . Substituted Pyrrololactams via Ring Expansion of Spiro-2H-pyrroles from Intermolecular Alkyne–Isocyanide Click Reactions. Organic Letters 2017, 19 (3) , 628-631.
    4. Mario Fiore, Stefano Forli, and Fabrizio Manetti . Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials. Journal of Medicinal Chemistry 2016, 59 (8) , 3609-3634.
    5. Victor J. Cee, Frank Chavez, Jr., Bradley Herberich, Brian A. Lanman, Liping H. Pettus, Anthony B. Reed, Bin Wu, Ryan P. Wurz, Kristin L. Andrews, Jie Chen, Dean Hickman, Jimmy Laszlo, III, Matthew R. Lee, Nadia Guerrero, Bethany K. Mattson, Yen Nguyen, Christopher Mohr, Karen Rex, Christine E. Sastri, Paul Wang, Qiong Wu, Tian Wu, Yang Xu, Yihong Zhou, Jeffrey T. Winston, J. Russell Lipford, Andrew S. Tasker, and Hui-Ling Wang . Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors. ACS Medicinal Chemistry Letters 2016, 7 (4) , 408-412.
    6. Jason G. Kettle, Peter Ballard, Catherine Bardelle, Mark Cockerill, Nicola Colclough, Susan E. Critchlow, Judit Debreczeni, Gary Fairley, Shaun Fillery, Mark A. Graham, Louise Goodwin, Sylvie Guichard, Kevin Hudson, Richard A. Ward, and David Whittaker . Discovery and Optimization of a Novel Series of Dyrk1B Kinase Inhibitors To Explore a MEK Resistance Hypothesis. Journal of Medicinal Chemistry 2015, 58 (6) , 2834-2844.
    7. John G. Cumming, Judit É. Debreczeni, Fredrik Edfeldt, Emma Evertsson, Martin Harrison, Geoffrey A. Holdgate, Michael J. James, Scott G. Lamont, Keith Oldham, Jane E. Sullivan, and Stuart L. Wells . Discovery and Characterization of MAPK-activated Protein Kinase-2 Prevention of Activation Inhibitors. Journal of Medicinal Chemistry 2015, 58 (1) , 278-293.
    8. Atli Thorarensen, Mary Ellen Banker, Andrew Fensome, Jean-Baptiste Telliez, Brian Juba, Fabien Vincent, Robert M. Czerwinski, and Agustin Casimiro-Garcia . ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling. ACS Chemical Biology 2014, 9 (7) , 1552-1558.
    9. Fang-Fang Zhuo, Wen-Wen Xie, Yong-Xin Yang, Lei Zhang, Pei Wang, Rui Yuan, and Chao-Shan Da . TMEDA-Assisted Effective Direct Ortho Arylation of Electron-Deficient N-Heteroarenes with Aromatic Grignard Reagents. The Journal of Organic Chemistry 2013, 78 (7) , 3243-3249.
    10. Philip Cohen and Dario R. Alessi . Kinase Drug Discovery – What’s Next in the Field?. ACS Chemical Biology 2013, 8 (1) , 96-104.
    11. Anthony A. Estrada, Xingrong Liu, Charles Baker-Glenn, Alan Beresford, Daniel J. Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Xiao Ding, Antonio G. DiPasquale, Sara L. Dominguez, Jennafer Dotson, Jason Drummond, Michael Flagella, Sean Flynn, Reina Fuji, Andrew Gill, Janet Gunzner-Toste, Seth F. Harris, Timothy P. Heffron, Tracy Kleinheinz, Donna W. Lee, Claire E. Le Pichon, Joseph P. Lyssikatos, Andrew D. Medhurst, John G. Moffat, Susmith Mukund, Kevin Nash, Kimberly Scearce-Levie, Zejuan Sheng, Daniel G. Shore, Thuy Tran, Naimisha Trivedi, Shumei Wang, Shuo Zhang, Xiaolin Zhang, Guiling Zhao, Haitao Zhu, and Zachary K. Sweeney . Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors. Journal of Medicinal Chemistry 2012, 55 (22) , 9416-9433.
    12. Tomomi Kosugi, Dale R. Mitchell, Aiko Fujino, Minoru Imai, Mika Kambe, Shinji Kobayashi, Hiroaki Makino, Yohei Matsueda, Yasuhiro Oue, Kanji Komatsu, Keiichiro Imaizumi, Yuri Sakai, Satoshi Sugiura, Osami Takenouchi, Gen Unoki, Yuko Yamakoshi, Vicky Cunliffe, Julie Frearson, Richard Gordon, C. John Harris, Heidi Kalloo-Hosein, Joelle Le, Gita Patel, Donald J. Simpson, Brad Sherborne, Peter S. Thomas, Naotaka Suzuki, Midori Takimoto-Kamimura, and Ken-ichiro Kataoka . Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAP-K2) as an Antiinflammatory Target: Discovery and in Vivo Activity of Selective Pyrazolo[1,5-a]pyrimidine Inhibitors Using a Focused Library and Structure-Based Optimization Approach. Journal of Medicinal Chemistry 2012, 55 (15) , 6700-6715.
    13. Huifen Chen, Bryan K. Chan, Jason Drummond, Anthony A. Estrada, Janet Gunzner-Toste, Xingrong Liu, Yichin Liu, John Moffat, Daniel Shore, Zachary K. Sweeney, Thuy Tran, Shumei Wang, Guiling Zhao, Haitao Zhu, and Daniel J. Burdick . Discovery of Selective LRRK2 Inhibitors Guided by Computational Analysis and Molecular Modeling. Journal of Medicinal Chemistry 2012, 55 (11) , 5536-5545.
    14. Senthil Natesan, Rajesh Subramaniam, Charles Bergeron, and Stefan Balaz . Binding Affinity Prediction for Ligands and Receptors Forming Tautomers and Ionization Species: Inhibition of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2). Journal of Medicinal Chemistry 2012, 55 (5) , 2035-2047.
    15. Jun Qin, Pawan Dhondi, Xianhai Huang, Robert Aslanian, James Fossetta, Fang Tian, Daniel Lundell, and Anandan Palani . Discovery of a Potent Dihydrooxadiazole Series of Non-ATP-Competitive MK2 (MAPKAPK2) Inhibitors. ACS Medicinal Chemistry Letters 2012, 3 (2) , 100-105.
    16. Margaret R. McLellan, M. Dominic Ryan, and Curt M. Breneman . Rank Order Entropy: Why One Metric Is Not Enough. Journal of Chemical Information and Modeling 2011, 51 (9) , 2302-2319.
    17. Xiaohua Huang, Gerald W. Shipps, Jr., Cliff C. Cheng, Peter Spacciapoli, Xingmin Zhang, Mark A. McCoy, Daniel F. Wyss, Xianshu Yang, Abdelghani Achab, Kyle Soucy, Donna K. Montavon, Denise M. Murphy, and Charles E. Whitehurst . Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors. ACS Medicinal Chemistry Letters 2011, 2 (8) , 632-637.
    18. Géraldine Calvet, Marion Livecchi, and Frédéric Schmidt . Synthesis of Polysubstituted 5-Azaindoles via Palladium-Catalyzed Heteroannulation of Diarylalkynes. The Journal of Organic Chemistry 2011, 76 (11) , 4734-4740.
    19. Minoru Ishikawa and Yuichi Hashimoto . Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry. Journal of Medicinal Chemistry 2011, 54 (6) , 1539-1554.
    20. Julen Oyarzabal, Natasha Zarich, María Isabel Albarran, Irene Palacios, Manuel Urbano-Cuadrado, Genoveva Mateos, Isabel Reymundo, Obdulia Rabal, Antonio Salgado, Ana Corrionero, Jesús Fominaya, Joaquin Pastor, and James R. Bischoff. Discovery of Mitogen-Activated Protein Kinase-Interacting Kinase 1 Inhibitors by a Comprehensive Fragment-Oriented Virtual Screening Approach. Journal of Medicinal Chemistry 2010, 53 (18) , 6618-6628.
    21. Maria Menichincheri, Alberto Bargiotti, Jens Berthelsen, Jay A. Bertrand, Roberto Bossi, Antonella Ciavolella, Alessandra Cirla, Cinzia Cristiani, Valter Croci, Roberto D’Alessio, Marina Fasolini, Francesco Fiorentini, Barbara Forte, Antonella Isacchi, Katia Martina, Antonio Molinari, Alessia Montagnoli, Paolo Orsini, Fabrizio Orzi, Enrico Pesenti, Daniele Pezzetta, Antonio Pillan, Italo Poggesi, Fulvia Roletto, Alessandra Scolaro, Marco Tatò, Marcellino Tibolla, Barbara Valsasina, Mario Varasi, Daniele Volpi, Corrado Santocanale and Ermes Vanotti . First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Discovery. Journal of Medicinal Chemistry 2009, 52 (2) , 293-307.
    22. Roland E. Dolle, Bertrand Le Bourdonnec, Allan J. Goodman, Guillermo A. Morales, Craig J. Thomas and Wei Zhang . Comprehensive Survey of Chemical Libraries for Drug Discovery and Chemical Biology: 2007. Journal of Combinatorial Chemistry 2008, 10 (6) , 753-802.
    23. Ermes Vanotti, Raffaella Amici, Alberto Bargiotti, Jens Berthelsen, Roberta Bosotti, Antonella Ciavolella, Alessandra Cirla, Cinzia Cristiani, Roberto D’Alessio, Barbara Forte, Antonella Isacchi, Katia Martina, Maria Menichincheri, Antonio Molinari, Alessia Montagnoli, Paolo Orsini, Antonio Pillan, Fulvia Roletto, Alessandra Scolaro, Marcellino Tibolla, Barbara Valsasina, Mario Varasi, Daniele Volpi and Corrado Santocanale. Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potential Antitumor Agents. 1. Synthesis and Structure–Activity Relationships. Journal of Medicinal Chemistry 2008, 51 (3) , 487-501.
    24. D. Alimbetov, B. Umbayev, A. Tsoy, D. Begimbetova, T. Davis, D. Kipling, Sh. Askarova. Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment. BMC Cancer 2023, 23 (1)
    25. Ami N. Saito, Eisuke Ota, Norihito Nakamichi, Junichiro Yamaguchi. Development of Plant Circadian Clock Modulators. Journal of Synthetic Organic Chemistry, Japan 2023, 81 (7) , 718-730.
    26. Suroor Fatima Rizvi, Adria Hasan, Sana Parveen, Snober S. Mir. Untangling the complexity of heat shock protein 27 in cancer and metastasis. Archives of Biochemistry and Biophysics 2023, 736 , 109537.
    27. David Gordon, Alan Kivitz, Atul Singhal, David Burt, Madison C. Bangs, Emma E. Huff, Heidi Rath Hope, Joseph B. Monahan. Selective Inhibition of the MK2 Pathway: Data From a Phase  IIa Randomized Clinical Trial in Rheumatoid Arthritis. ACR Open Rheumatology 2023, 5 (2) , 63-70.
    28. Toru Suzuki, Miyuki Hoshina, Saori Nishijima, Naosuke Hoshina, Chisato Kikuguchi, Takumi Tomohiro, Akira Fukao, Toshinobu Fujiwara, Tadashi Yamamoto. Regulation of CCR4-NOT complex deadenylase activity and cellular responses by MK2-dependent phosphorylation of CNOT2. RNA Biology 2022, 19 (1) , 234-246.
    29. Hedvig Bölcskei, Német-Hanzelik Andrea, György Keglevich. Synthesis of 5-membered Heteroaryl-substituted Benzyloxy-benzaldehydes by the Suzuki-Miyaura Coupling Reaction. Current Organic Chemistry 2022, 26 (18) , 1725-1733.
    30. Yunze Wang, Qingyu Lin, Hongcheng Shi, Dengfeng Cheng. Fluorine-18: Radiochemistry and Target-Specific PET Molecular Probes Design. Frontiers in Chemistry 2022, 10
    31. Rachel L. Howells, Scott G. Lamont, Thomas M. McGuire, Samantha Hughes, Rachel Borrows, Gary Fairley, Lyman J. L. Feron, Ryan D. R. Greenwood, Eva Lenz, Emma Grant, Iain Simpson. Synthesis of Novel Pyrazine-Substituted 1H-Pyrrole-2-carboxamides and Related Tethered Heterocycles. Synthesis 2022, 54 (09) , 2267-2281.
    32. Fiona Scott, Angela M. Fala, Jessica E. Takarada, Mihaela P. Ficu, Lewis E. Pennicott, Tristan D. Reuillon, Rafael M. Couñago, Katlin B. Massirer, Jonathan M. Elkins, Simon E. Ward. Development of dihydropyrrolopyridinone-based PKN2/PRK2 chemical tools to enable drug discovery. Bioorganic & Medicinal Chemistry Letters 2022, 60 , 128588.
    33. Ibrahim Malami, Aisha Muktar Bunza, Alhassan Muhammad Alhassan, Aliyu Muhammad, Ibrahim Babangida Abubakar, Abdulmajeed Yunusa, Peter M. Waziri, Imaobong C. Etti. Dihydroartemisinin as a potential drug candidate for cancer therapy: a structural-based virtual screening for multitarget profiling. Journal of Biomolecular Structure and Dynamics 2022, 40 (3) , 1347-1362.
    34. Deri Morgan, Kiersten L. Berggren, Colby D. Spiess, Hannah M. Smith, Ajay Tejwani, Scott J. Weir, Christopher E. Lominska, Sufi M. Thomas, Gregory N. Gan. Mitogen‐activated protein kinase‐activated protein kinase‐2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancer. Molecular Carcinogenesis 2022, 61 (2) , 173-199.
    35. Simona Nemska, François Daubeuf, Adeline Obrecht, Dominique Israel-Biet, Marc Stern, Romain Kessler, Antoine Roux, Reza Tavakoli, Pascal Villa, Adrien Tissot, Richard Danger, Laurent Reber, Eugénie Durand, Aurore Foureau, Sophie Brouard, Antoine Magnan, Nelly Frossard, . Overexpression of the MSK1 Kinase in Patients With Chronic Lung Allograft Dysfunction and Its Confirmed Role in a Murine Model. Transplantation 2021, 105 (6) , 1212-1224.
    36. Ivar S. Stein, Deborah K. Park, Nicole Claiborne, Karen Zito. Non-ionotropic NMDA receptor signaling gates bidirectional structural plasticity of dendritic spines. Cell Reports 2021, 34 (4) , 108664.
    37. Maud Bollenbach, Simona Nemska, Patrick Wagner, Guillaume Camelin, François Daubeuf, Adeline Obrecht, Pascal Villa, Didier Rognan, Frédéric Bihel, Jean-Jacques Bourguignon, Martine Schmitt, Nelly Frossard. Design, Synthesis and Biological Evaluation of Arylpyridin-2-yl Guanidine Derivatives and Cyclic Mimetics as Novel MSK1 Inhibitors. An Application in an Asthma Model. Molecules 2021, 26 (2) , 391.
    38. Rabdan M. Tikhov, Nikolai Yu. Kuznetsov. Construction of piperidine-2,4-dione-type azaheterocycles and their application in modern drug development and natural product synthesis. Organic & Biomolecular Chemistry 2020, 18 (15) , 2793-2812.
    39. Sourabh Soni, Prince Anand, Yogendra S. Padwad. MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression. Journal of Experimental & Clinical Cancer Research 2019, 38 (1)
    40. Hedvig Bölcskei, Andrea Német-Hanzelik, Zsófia Dubrovay, Viktor Háda, György Keglevich. Synthesis of Phenyl- and Pyridyl-substituted Benzyloxybenzaldehydes by Suzuki-Miyaura Coupling Reactions. Letters in Drug Design & Discovery 2019, 16 (11) , 1248-1257.
    41. Rachel Archer, Emma Hock, Jean Hamilton, John Stevens, Munira Essat, Edith Poku, Mark Clowes, Abdullah Pandor, Matt Stevenson. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technology Assessment 2018, 22 (66) , 1-294.
    42. Kranthi Kumar Konidala, Uma Devi Bommu, Suneetha Yeguvapalli, Neeraja Pabbaraju. In silico insights into prediction and analysis of potential novel pyrrolopyridine analogs against human MAPKAPK-2: a new SAR-based hierarchical clustering approach. 3 Biotech 2018, 8 (9)
    43. Yizhu Li, Frederik Köpper, Matthias Dobbelstein. Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin. Cancer Letters 2018, 428 , 45-54.
    44. Ana Henriques, Vasiliki Koliaraki, George Kollias. Mesenchymal MAPKAPK2/HSP27 drives intestinal carcinogenesis. Proceedings of the National Academy of Sciences 2018, 115 (24)
    45. Nathan J. Gesmundo, Bérengère Sauvagnat, Patrick J. Curran, Matthew P. Richards, Christine L. Andrews, Peter J. Dandliker, Tim Cernak. Nanoscale synthesis and affinity ranking. Nature 2018, 557 (7704) , 228-232.
    46. Tallapally Swamy, Basi V. Subba Reddy, René Grée, Vadde Ravinder. Substrate‐Directed C‐H Functionalization of 2‐Aryl Pyridines by Transition Metal Complexes. ChemistrySelect 2018, 3 (1) , 47-70.
    47. Kenji Tanabe. Microtubule Depolymerization by Kinase Inhibitors: Unexpected Findings of Dual Inhibitors. International Journal of Molecular Sciences 2017, 18 (12) , 2508.
    48. Rakesh Kumar Singh, Abul Kalam Najmi, Sunanda Ghosh Dastidar. Biological functions and role of mitogen-activated protein kinase activated protein kinase 2 (MK2) in inflammatory diseases. Pharmacological Reports 2017, 69 (4) , 746-756.
    49. Yves Leestemaker, Annemieke de Jong, Katharina F. Witting, Renske Penning, Karianne Schuurman, Boris Rodenko, Esther A. Zaal, Bert van de Kooij, Stefan Laufer, Albert J.R. Heck, Jannie Borst, Wiep Scheper, Celia R. Berkers, Huib Ovaa. Proteasome Activation by Small Molecules. Cell Chemical Biology 2017, 24 (6) , 725-736.e7.
    50. Lenka Munoz. Non-kinase targets of protein kinase inhibitors. Nature Reviews Drug Discovery 2017, 16 (6) , 424-440.
    51. Md Jakir Hossain, Radu Tanasescu, Bruno Gran. Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2. Journal of Neuroimmunology 2017, 304 , 11-20.
    52. Doan Duy Hai Tran, Alexandra Koch, Aldrige Allister, Shashank Saran, Florian Ewald, Martina Koch, Björn Nashan, Teruko Tamura. Treatment with MAPKAP2 (MK2) inhibitor and DNA methylation inhibitor, 5-aza dC, synergistically triggers apoptosis in hepatocellular carcinoma (HCC) via tristetraprolin (TTP). Cellular Signalling 2016, 28 (12) , 1872-1880.
    53. Ryan Greenwood, Kay Yeung. The synthesis of novel pyrrololactams and their boronate ester derivatives. Tetrahedron Letters 2016, 57 (51) , 5812-5814.
    54. Junichi Maruyama, Yumie Kobayashi, Tsuyoshi Umeda, Alain Vandewalle, Kohsuke Takeda, Hidenori Ichijo, Isao Naguro. Osmotic stress induces the phosphorylation of WNK4 Ser575 via the p38MAPK-MK pathway. Scientific Reports 2016, 6 (1)
    55. Dauren Alimbetov, Terence Davis, Amy J. C. Brook, Lynne S. Cox, Richard G. A. Faragher, Talgat Nurgozhin, Zhaxybay Zhumadilov, David Kipling. Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2. Biogerontology 2016, 17 (2) , 305-315.
    56. P E Brennan. Deciphering the true antiproliferative target of an MK2 activation inhibitor in glioblastoma. Cell Death & Disease 2016, 7 (1) , e2069-e2069.
    57. FMS Gurgis, MC Åkerfeldt, B Heng, C Wong, S Adams, GJ Guillemin, TG Johns, M Chircop, L Munoz. Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2. Cell Death Discovery 2015, 1 (1)
    58. Thanh Huong Nguyen Ho-Bouldoires, Audrey Clapéron, Martine Mergey, Dominique Wendum, Christèle Desbois-Mouthon, Sylvana Tahraoui, Laetitia Fartoux, Hamza Chettouh, Fatiha Merabtene, Olivier Scatton, Matthias Gaestel, Françoise Praz, Chantal Housset, Laura Fouassier. Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells. Free Radical Biology and Medicine 2015, 89 , 34-46.
    59. Songnian Lin, Sunita Malkani, Matthew Lombardo, Lihu Yang, Sander G. Mills, Kevin Chapman, James E. Thompson, Wen Xiao Zhang, Ruixiu Wang, Rose M. Cubbon, Edward A. O’Neill, Jeffrey J. Hale. Design, synthesis, and biological evaluation of aminopyrazine derivatives as inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). Bioorganic & Medicinal Chemistry Letters 2015, 25 (22) , 5402-5408.
    60. Mark Bagley, Mohammed Baashen, Irina Chuckowree, Jessica Dwyer, David Kipling, Terence Davis. Microwave-Assisted Synthesis of a MK2 Inhibitor by Suzuki-Miyaura Coupling for Study in Werner Syndrome Cells. Pharmaceuticals 2015, 8 (2) , 257-276.
    61. On Ying Yuen, Mueangkaew Charoensak, Chau Ming So, Chutima Kuhakarn, Fuk Yee Kwong. A General Direct Arylation of Polyfluoroarenes with Heteroaryl and Aryl Chlorides Catalyzed by Palladium Indolylphosphine Complexes. Chemistry – An Asian Journal 2015, 10 (4) , 857-861.
    62. Terence Davis, Hannah S. E. Tivey, Amy J. C. Brook, David Kipling. Nijmegen breakage syndrome fibroblasts expressing the C-terminal truncated NBNp70 protein undergo p38/MK2-dependent premature senescence. Biogerontology 2015, 16 (1) , 43-51.
    63. Christopher Tiedje, Michal Lubas, Mohammad Tehrani, Manoj B. Menon, Natalia Ronkina, Simon Rousseau, Philip Cohen, Alexey Kotlyarov, Matthias Gaestel. p38 MAPK /MK2-mediated phosphorylation of RBM7 regulates the human nuclear exosome targeting complex. RNA 2015, 21 (2) , 262-278.
    64. Jennifer A. Corcoran, Benjamin P. Johnston, Craig McCormick, . Viral Activation of MK2-hsp27-p115RhoGEF-RhoA Signaling Axis Causes Cytoskeletal Rearrangements, P-body Disruption and ARE-mRNA Stabilization. PLoS Pathogens 2015, 11 (1) , e1004597.
    65. Minoru Ishikawa, Yuichi Hashimoto. Improving the Water-Solubility of Compounds by Molecular Modification to Disrupt Crystal Packing. 2015, 747-765.
    66. Pierfausto Seneci. Targeting the Protein Quality Control (PQC) Machinery. 2015, 25-71.
    67. Alexey Shiryaev, Gianina Dumitriu, Ugo Moens. Distinct roles of MK2 and MK5 in cAMP/PKA- and stress/p38MAPK-induced heat shock protein 27 phosphorylation. Journal of Molecular Signaling 2014, 6 , 4.
    68. Nanda Kumar Sasi, Kanchan Tiwari, Fen-Fen Soon, Dorine Bonte, Tong Wang, Karsten Melcher, H. Eric Xu, Michael Weinreich, . The Potent Cdc7-Dbf4 (DDK) Kinase Inhibitor XL413 Has Limited Activity in Many Cancer Cell Lines and Discovery of Potential New DDK Inhibitor Scaffolds. PLoS ONE 2014, 9 (11) , e113300.
    69. Maria Katsogiannou, Claudia Andrieu, Palma Rocchi. Heat shock protein 27 phosphorylation state is associated with cancer progression. Frontiers in Genetics 2014, 5
    70. Mark C Bagley, Mohammed Baashen, Jessica Dwyer, Pierre Milbeo, David Kipling, Terence Davis. Microwave-assisted synthesis of MK2 inhibitors for targeting p38 MAPK signal transduction in Werner syndrome cells. 2014, 86-104.
    71. Eslam Pourbasheer, Roya Bazl, Massoud Amanlou. Molecular docking and 3D-QSAR studies on the MAPKAP-K2 inhibitors. Medicinal Chemistry Research 2014, 23 (5) , 2252-2263.
    72. Frederik Köpper, Anna Maria Binkowski, Cathrin Bierwirth, Matthias Dobbelstein. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells. Cell Cycle 2014, 13 (6) , 884-889.
    73. Inger Lindin, Yimingjiang Wuxiuer, Aina Ravna, Ugo Moens, Ingebrigt Sylte. Comparative Molecular Dynamics Simulations of Mitogen-Activated Protein Kinase-Activated Protein Kinase 5. International Journal of Molecular Sciences 2014, 15 (3) , 4878-4902.
    74. Fadi Maged Shokry Gurgis, William Ziaziaris, Lenka Munoz. Mitogen-Activated Protein Kinase–Activated Protein Kinase 2 in Neuroinflammation, Heat Shock Protein 27 Phosphorylation, and Cell Cycle: Role and Targeting. Molecular Pharmacology 2014, 85 (2) , 345-356.
    75. Aiko Fujino, Kei Fukushima, Takaharu Kubota, Yoshiyuki Matsumoto, Midori Takimoto-Kamimura. Structure of the β-form of human MK2 in complex with the non-selective kinase inhibitor TEI-L03090. Acta Crystallographica Section F Structural Biology and Crystallization Communications 2013, 69 (12) , 1344-1348.
    76. Terence Davis, Michal J Rokicki, Mark C Bagley, David Kipling. The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome. Chemistry Central Journal 2013, 7 (1)
    77. Aiko Fujino, Kei Fukushima, Takaharu Kubota, Tomomi Kosugi, Midori Takimoto-Kamimura. Crystal structure of human cyclin-dependent kinase-2 complex with MK2 inhibitor TEI-I01800: insight into the selectivity. Journal of Synchrotron Radiation 2013, 20 (6) , 905-909.
    78. Frederik Köpper, Cathrin Bierwirth, Margarete Schön, Meike Kunze, Ingegerd Elvers, Dominique Kranz, Priyanka Saini, Manoj B. Menon, David Walter, Claus Storgaard Sørensen, Matthias Gaestel, Thomas Helleday, Michael P. Schön, Matthias Dobbelstein. Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proceedings of the National Academy of Sciences 2013, 110 (42) , 16856-16861.
    79. Tai-Jin Wang, Lu Zhou, Jia Fei, Zi-Cheng Li, Lu-fen He. Applications of 3D-QSAR and structure-based pharmacophore modeling, virtual screening, ADMET, and molecular docking of putative MAPKAP-K2 (MK2) inhibitors. Medicinal Chemistry Research 2013, 22 (10) , 4818-4829.
    80. Matthias Gaestel. What goes up must come down: molecular basis of MAPKAP kinase 2/3-dependent regulation of the inflammatory response and its inhibition. bchm 2013, 394 (10) , 1301-1315.
    81. J.C. Felger, F.E. Lotrich. Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246 , 199-229.
    82. Thomas Troxler, Paulette Greenidge, Kaspar Zimmermann, Sandrine Desrayaud, Peter Drückes, Tatjana Schweizer, Daniela Stauffer, Giorgio Rovelli, Derya R. Shimshek. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2. Bioorganic & Medicinal Chemistry Letters 2013, 23 (14) , 4085-4090.
    83. Linda D. Bobo, Rana E. El Feghaly, Yee-Shiuan Chen, Erik R. Dubberke, Zhuolin Han, Alexandra H. Baker, Jinmei Li, Carey-Ann D. Burnham, David B. Haslam, . MAPK-Activated Protein Kinase 2 Contributes to Clostridium difficile-Associated Inflammation. Infection and Immunity 2013, 81 (3) , 713-722.
    84. Adam J. Guess, Rose Ayoob, Melinda Chanley, Joshua Manley, Mariana M. Cajaiba, Shipra Agrawal, Ruma Pengal, Amy L. Pyle, Brian Becknell, Jeffrey B. Kopp, Natalia Ronkina, Matthias Gaestel, Rainer Benndorf, William E. Smoyer, . Crucial Roles of the Protein Kinases MK2 and MK3 in a Mouse Model of Glomerulonephritis. PLoS ONE 2013, 8 (1) , e54239.
    85. Nadia Moretto, Serena Bertolini, Claudia Iadicicco, Gessica Marchini, Manminder Kaur, Giorgia Volpi, Riccardo Patacchini, Dave Singh, Fabrizio Facchinetti. Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. American Journal of Physiology-Lung Cellular and Molecular Physiology 2012, 303 (10) , L929-L938.
    86. Upasna Kaushik, Vikas Sharma, Vipin Kumar. Computation of pharmacophore models for the prediction of mitogen-activated protein kinase activated protein kinase-2 inhibitory activity of pyrrolopyridines. Medicinal Chemistry Research 2012, 21 (11) , 3777-3784.
    87. JEREMY J. EDMUNDS, ROBERT V. TALANIAN. MAPKAP Kinase 2 (MK2) as a Target for Anti-inflammatory Drug Discovery. 2012, 158-180.
    88. Ming Hao, Hong Ren, Fang Luo, Shuwei Zhang, Jieshan Qiu, Mingjuan Ji, Hongzong Si, Guohui Li. A Computational Study on Thiourea Analogs as Potent MK-2 Inhibitors. International Journal of Molecular Sciences 2012, 13 (6) , 7057-7079.
    89. Peter Birner, Andrea Beer, Ursula Vinatzer, Susanne Stary, Romana Höftberger, Nadine Nirtl, Fritz Wrba, Berthold Streubel, Sebastian F. Schoppmann. MAPKAP Kinase 2 Overexpression Influences Prognosis in Gastrointestinal Stromal Tumors and Associates with Copy Number Variations on Chromosome 1 and Expression of p38 MAP Kinase and ETV1. Clinical Cancer Research 2012, 18 (7) , 1879-1887.
    90. Jia-Heng Shie, Hsin-Tzu Liu, Hann-Chorng Kuo. Increased Cell Apoptosis of Urothelium Mediated by Inflammation in Interstitial Cystitis/Painful Bladder Syndrome. Urology 2012, 79 (2) , 484.e7-484.e13.
    91. Ning Shi, Wei-Bing Xie, Shi-You Chen. Cell Division Cycle 7 Is a Novel Regulator of Transforming Growth Factor-β-induced Smooth Muscle Cell Differentiation. Journal of Biological Chemistry 2012, 287 (9) , 6860-6867.
    92. Matthias Gaestel, Alexey Kotlyarov. Small-Molecule Protein and Lipid Kinase Inhibitors in Inflammation and Specific Models for Their Evaluation. 2012, 35-44.
    93. Arthur Oubrie, Allard Kaptein, Edwin de Zwart, Niels Hoogenboom, Rianne Goorden, Bas van de Kar, Maaike van Hoek, Vera de Kimpe, Ruud van der Heijden, Judith Borsboom, Bert Kazemier, Jeroen de Roos, Michiel Scheffers, Jos Lommerse, Carsten Schultz-Fademrecht, Tjeerd Barf. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series. Bioorganic & Medicinal Chemistry Letters 2012, 22 (1) , 613-618.
    94. Ashwin U. Rao, Dong Xiao, Xianhai Huang, Wei Zhou, James Fossetta, Dan Lundell, Fang Tian, Prashant Trivedi, Robert Aslanian, Anandan Palani. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors. Bioorganic & Medicinal Chemistry Letters 2012, 22 (2) , 1068-1072.
    95. Alasdair J. Scott, Kieran P. O'Dea, David O'Callaghan, Lynn Williams, Justina O. Dokpesi, Louise Tatton, Jonathan M. Handy, Philip J. Hogg, Masao Takata. Reactive Oxygen Species and p38 Mitogen-activated Protein Kinase Mediate Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM-17) Activation in Primary Human Monocytes. Journal of Biological Chemistry 2011, 286 (41) , 35466-35476.
    96. Ya Jing FENG, Yong Yu LI. The role of p38 mitogen‐activated protein kinase in the pathogenesis of inflammatory bowel disease. Journal of Digestive Diseases 2011, 12 (5) , 327-332.
    97. Ruma Pengal, Adam J. Guess, Shipra Agrawal, Joshua Manley, Richard F. Ransom, Robert J. Mourey, Rainer Benndorf, William E. Smoyer. Inhibition of the protein kinase MK-2 protects podocytes from nephrotic syndrome-related injury. American Journal of Physiology-Renal Physiology 2011, 301 (3) , F509-F519.
    98. Thomas Hjelmgaard, Sophie Faure, Dan Staerk, Claude Taillefumier, John Nielsen. Expedient Solution‐Phase Synthesis and NMR Studies of Arylopeptoids. European Journal of Organic Chemistry 2011, 2011 (22) , 4121-4132.
    99. Allard Kaptein, Arthur Oubrie, Edwin de Zwart, Niels Hoogenboom, Joeri de Wit, Bas van de Kar, Maaike van Hoek, Gerard Vogel, Vera de Kimpe, Carsten Schultz-Fademrecht, Judith Borsboom, Mario van Zeeland, Judith Versteegh, Bert Kazemier, Jeroen de Roos, Frank Wijnands, John Dulos, Martin Jaeger, Paula Leandro-Garcia, Tjeerd Barf. Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors. Bioorganic & Medicinal Chemistry Letters 2011, 21 (12) , 3823-3827.
    100. Tjeerd Barf, Allard Kaptein, Sander de Wilde, Ruud van der Heijden, Richard van Someren, Dennis Demont, Carsten Schultz-Fademrecht, Judith Versteegh, Mario van Zeeland, Nicole Seegers, Bert Kazemier, Bas van de Kar, Maaike van Hoek, Jeroen de Roos, Henri Klop, Ruben Smeets, Claudia Hofstra, Jorrit Hornberg, Arthur Oubrie. Structure-based lead identification of ATP-competitive MK2 inhibitors. Bioorganic & Medicinal Chemistry Letters 2011, 21 (12) , 3818-3822.
    Load all citations

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect